A new study published in April sheds light on the concerns of anesthesiologists across the United States related to the perioperative management of patients taking glucagon-like peptide-1 (GLP-1) agonists, a class of drugs now commonly prescribed for both diabetes and cosmetic weight loss. GLP-1 agonists such as semaglutide (marketed as Ozempic and Wegovy) have surged…
